Highlights:
- Group Turnover reached £991.6m
- Underlying PBIT of £27.9m
- Strengthened [...] Read more »
Highlights:
MADRI, Feb. 27, 2026 (GLOBE NEWSWIRE) -- A Neinor Homes (“Neinor”) encerrou o AF25 com destaques nos resultados operacionais e financeiros. Durante o AF25, mas excluindo o impacto da aquisição de [...] Read more »
MADRID, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Neinor Homes („Neinor“) hat das Geschäftsjahr 2025 mit starken operativen und finanziellen Ergebnissen abgeschlossen. Im Geschäftsjahr 2025 – ohne [...] Read more »
MADRID, 27 févr. 2026 (GLOBE NEWSWIRE) -- Neinor Homes (« Neinor ») a clôturé l’exercice 2025 en affichant des résultats d’exploitation et financiers exemplaires. Au cours de [...] Read more »
MADRID, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Neinor Homes (“Neinor”) closed FY25 with standout operational and financial results. During FY25 and excluding the impact from acquiring a 79.2% stake in AEDAS, Neinor [...] Read more »
Revenue Increases 568% Year–over–Year and 78% Sequentially to $4.94 Million
Q3 2025 Net Income Reaches $65.59 Million Driven by Ethereum Accumulation
Read more »
استمرار التوسع الدولي كمحرك رئيسي [...] Read more »
Revenue growth of 12.4%, and 47% in constant currency for Q1 2025 over Q1 2024
Achieved $0.8 million in Net Profit in Q1 2025
Dollar pegged revenue increased [...] Read more »
JERUSALEM, May 09, 2025 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptide and protein replacement therapies, today reported financial results and key business updates for [...] Read more »
فيلنيوس، ليتوانيا, April 28, 2025 (GLOBE NEWSWIRE) —
Read more »
VILNIUS, Lithuania, April 25, 2025 (GLOBE NEWSWIRE) — Read more »
Highlights
JERUSALEM, March 28, 2025 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and proteins replacement therapies, today reported financial results and key business [...] Read more »